Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Dylan Fulford

Physician Assistant Wichita Falls, TX Physician Assistant

NPI 1003585381 CMS profile 11270031

2726 Shepherds Gln, Wichita Falls, TX 76308

Open in the dashboard

General payments

$2,348

70 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Dylan Fulford of Wichita Falls, TX is reported in the CMS Open Payments database as having received $2,348 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,044 9
2022 General $1,177 50
2021 General $127 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dylan Fulford
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Dylan Fulford were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Dylan Fulford Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $127 $132 $37–$438 $132
2022 $1,177 $155 $48–$522 $149
2023 $1,044 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. MicroPort Orthopedics Inc $1,121 11 payments
  2. Exactech, Inc. $531 3 payments
  3. Stryker Corporation $502 34 payments
  4. Medacta USA, Inc. $121 20 payments
  5. Alafair Biosciences,Inc. $40 1 payment
  6. Medinc of Texas $33 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Travel and Lodging $1,234 8 payments
  2. Food and Beverage $1,114 62 payments
Products named General payments · program years 2021–2023
  1. MPO Hip System $1,057 9 payments
  2. Equinoxe $531 3 payments
  3. PROFYLE $322 22 payments
  4. OMEGA $191 11 payments
  5. MPO Medial Pivot Knee $64 2 payments
  6. MASTERLOC $50 7 payments
  7. GMK SPHERE $43 9 payments
  8. VersaWrap $40 1 payment
  9. GMRS $26 1 payment
  10. MPACT $15 2 payments
  11. Other $24 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

169

Median for Physician Assistant: 241

Drug cost

$10,668

Median for Physician Assistant: $4,110

Branded share of claims

24.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $9,638
Gabapentin Generic 28 $407
Meloxicam Generic 81 $279
Methylprednisolone Generic 19 $124
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $114
Acetaminophen-Codeine Acetaminophen With Codeine Brand 11 $105

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$53,075

Of which drugs: $10,485

Medicare patients

315

Average age 74

Services billed

2,431

185 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 39%
Ischemic heart disease 34%
Depression 33%
Chronic kidney disease 27%
COPD 24%
Osteoporosis 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 12 16 $6,402
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 73 996 $711

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record